Phase II Study of Pandemic Influenza Vaccine

Seqirus

Status and phase: Completed; Phase 2

Conditions: Influenza

Treatments: Biological: Pandemic Influenza Vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00320346

CSLCT-PAN-05-18

Details and patient eligibility

About

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic. This study will test the safety and immunogenicity of a H5N1 Pandemic Influenza Vaccine in healthy adults. The Study will also assess Lot to Lot consistency of the Pandemic Influenza Vaccine.

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Adults

Exclusion criteria

• Previous vaccination with an influenza Vaccine containing the H5N1 strain
• History of clinically significant medical conditions
• History of Guillian-Barre Syndrome or active Neurological disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind